Nicotine-1\'-N-oxide



Compound IDCDAMM02066
Common nameNicotine-1\'-N-oxide
IUPAC name3-(1-methyl-1-oxidopyrrolidin-1-ium-2-yl)pyridine
Molecular formulaC10H14N2O

Experimental data

Retention time7.5
Adduct[M+NH4]+
Actual mz196.144
Theoretical mz196.145
Error3.69
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.9849

Identifiers and class information

Inchi keyRWFBQHICRCUQJJ-UHFFFAOYNA-N
Smiles[O-][N+]1(C)CCCC1C=2C=NC=CC2
SuperclassOrganoheterocyclic compounds
ClassPyridines and derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)0
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)1
Molecular weight (mol_MW)178.233
Computed dipole moment(dipole)8.231
Total solvent accessible surface area (SASA)395.005
Hydrophobic component of SASA (FOSA)201.382
Hydrophilic component of SASA (FISA)55.281
Pie component of the SASA (PISA)138.342
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)652.622
Number of hydrogen bond donors (donorHB)0
Number of hydrogen bond acceptors (accptHB)4.5
Free energy of solvation of dipole (dip^2/V)0.103816
Index of cohesive interaction in solids (ACxDN^.5/SA)0
Globularity descriptor (glob)0.921165
Predicted polarizability in cubic angstroms (QPpolrz)21.285
Predicted hexadecane/gas partition coefficient (QPlogPC16)5.879
Predicted octanol/gas partition coefficient (QPlogPoct)10.238
Predicted water/gas partition coefficient (QPlogPw)6.419
Predicted octanol/water partition coefficient (QPlogPo/w)1.15
Predicted aqueous solubility (QPlogS)0.67
Conformation-independent predicted aqueous solubility (CIQPlogS)0.894
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.467
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)2962.58
Predicted brain/blood partition coefficient (QPlogBB)0.129
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)1600.18
Predicted skin permeability, log Kp (QPlogKp)-2.051
PM3 calculated ionization potential (IP(ev))9.611
PM3 calculated electron affinity (EA(eV))0.074
Number of likely metabolic reactions (#metab)4
Prediction of binding to human serum albumin (QPlogKhsa)-0.691
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)95.813
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)29.965
Number of nitrogen and oxygen atoms (#NandO)3
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P43681CHRNA4Neuronal acetylcholine receptor; alpha4/beta2T70967SwissTargetPrediction and SEA
P36544CHRNA7Neuronal acetylcholine receptor protein alpha-7 subunitT34429SwissTargetPrediction and SEA
P32297CHRNA3Neuronal acetylcholine receptor; alpha3/beta4T74166SwissTargetPrediction and SEA
P11509CYP2A6Cytochrome P450 2A6T06455SEA
P55786NPEPPSPuromycin-sensitive aminopeptidaseT15610SEA
P30926CHRNB4Neuronal acetylcholine receptor; alpha2/beta4T73724SwissTargetPrediction and SEA
Q15822CHRNA2Neuronal acetylcholine receptor; alpha2/beta2T55815SwissTargetPrediction
P17787CHRNB2Nicotinic acetylcholine receptor alpha2/beta2T82543SEA
P02708CHRNA1Neuronal acetylcholine receptor alpha-1T04689SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T70967DI0029Aneurysm/dissection[ICD-11: BD50]P43681CHRNA4
T70967DI0191Hypertensive crisis[ICD-11: BA03]P43681CHRNA4
T70967DI0196Hypotension[ICD-11: BA20-BA21]P43681CHRNA4
T34429DI0101Corneal disease[ICD-11: 9A76-9A78]P36544CHRNA7
T34429DI0370Schizophrenia[ICD-11: 6A20]P36544CHRNA7
T74166DI0105Cough[ICD-11: MD12]P32297CHRNA3
T06455DI0283Mycosis fungoides[ICD-11: 2B01]P11509CYP2A6
T06455DI0351Psoriasis[ICD-11: EA90]P11509CYP2A6
T15610DI0012Acute myeloid leukaemia[ICD-11: 2A60]P55786NPEPPS
T15610DI0284Myelodysplastic syndrome[ICD-11: 2A37]P55786NPEPPS
T73724DI0301Nicotine use disorder[ICD-11: 6C4A]P30926CHRNB4
T55815DI0101Corneal disease[ICD-11: 9A76-9A78]Q15822CHRNA2
T55815DI0117Depression[ICD-11: 6A70-6A7Z]Q15822CHRNA2
T55815DI0166Glaucoma[ICD-11: 9C61]Q15822CHRNA2
T55815DI0301Nicotine use disorder[ICD-11: 6C4A]Q15822CHRNA2
T55815DI0411Tonus and reflex abnormality[ICD-11: MB47]Q15822CHRNA2
T82543DI0301Nicotine use disorder[ICD-11: 6C4A]P17787CHRNB2
T04689DI0411Tonus and reflex abnormality[ICD-11: MB47]P02708CHRNA1

Copyright © 2025